Drugs / ISM3412
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06414460 | Apr 2025 → Mar 2028 expected | RET fusion positive cancer | InSilico Medicine | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISM3412 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06414460 ↗ |
| Route | Oral | “ISM3412 will be administered orally once daily.” NCT06414460 ↗ |